# Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

> **NCT01859962** · PHASE2 · COMPLETED · sponsor: **Presidio Pharmaceuticals, Inc.** · enrollment: 38 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** PPI-668
- **DRUG:** BI 207127 Dose 1
- **DRUG:** BI 207127 Dose 2
- **DRUG:** Faldaprevir
- **DRUG:** Ribavirin
- **DRUG:** BI 207127 Placebo

## Key facts

- **NCT ID:** NCT01859962
- **Lead sponsor:** Presidio Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2014-05
- **Final completion:** 2014-12
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2015-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01859962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01859962, "Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01859962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*